SrasV1, Main, Curation, bibRecord, 004426

Oligonucleotide-based antiviral strategies

Identifieur interne : 004426 ( Main/Curation ); précédent : 004425; suivant : 004427

Oligonucleotide-based antiviral strategies

Auteurs : S. Schubert [Allemagne] ; J. Kurreck [Allemagne]

Source :

Handbook of experimental pharmacology [ 0171-2004 ] ; 2006.

RBID : Pascal:06-0394917

Descripteurs français

KwdFr :
- ARN catalytique (pharmacologie), ARN catalytique (usage thérapeutique), Animaux, Antiviraux (pharmacologie), Antiviraux (usage thérapeutique), Humains, Maladies virales (traitement médicamenteux), Maladies virales (virologie), Oligonucléotides (pharmacologie), Oligonucléotides (usage thérapeutique), Oligonucléotides antisens (pharmacologie), Oligonucléotides antisens (usage thérapeutique), Petit ARN interférent (pharmacologie), Petit ARN interférent (usage thérapeutique).
MESH :
- pharmacologie : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- traitement médicamenteux : Maladies virales.
- usage thérapeutique : ARN catalytique, Antiviraux, Oligonucléotides, Oligonucléotides antisens, Petit ARN interférent.
- virologie : Maladies virales.
Pascal (Inist)
- Animaux, Humains, Oligonucléotide antisens, Antiviral, RNA catalytique, Silence expression génique, Article synthèse, ARN interférence, Interférence ARN.

English descriptors

KwdEn :
- Animals, Antisense oligonucleotide, Antiviral, Antiviral Agents (pharmacology), Antiviral Agents (therapeutic use), Gene silencing, Humans, Oligonucleotides (pharmacology), Oligonucleotides (therapeutic use), Oligonucleotides, Antisense (pharmacology), Oligonucleotides, Antisense (therapeutic use), RNA interference, RNA, Catalytic (pharmacology), RNA, Catalytic (therapeutic use), RNA, Small Interfering (pharmacology), RNA, Small Interfering (therapeutic use), Review, Ribozyme, Virus Diseases (drug therapy), Virus Diseases (virology).
MESH :
- chemical , pharmacology : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- chemical , therapeutic use : Antiviral Agents, Oligonucleotides, Oligonucleotides, Antisense, RNA, Catalytic, RNA, Small Interfering.
- drug therapy : Virus Diseases.
- virology : Virus Diseases.
- Animals, Humans.

Abstract

In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000473
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000517
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000446
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004647
to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002287
to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002287
to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002080
to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001444
to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001444
to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001444
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :003F71

Links to Exploration step

Pascal:06-0394917

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oligonucleotide-based antiviral strategies</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S." last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J." last="Kurreck">J. Kurreck</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0394917</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0394917 INIST</idno>
<idno type="RBID">Pascal:06-0394917</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000473</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000517</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000446</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000446</idno>
<idno type="wicri:doubleKey">0171-2004:2006:Schubert S:oligonucleotide:based:antiviral</idno>
<idno type="wicri:Area/Main/Merge">004647</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16594620</idno>
<idno type="wicri:Area/PubMed/Corpus">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002287</idno>
<idno type="wicri:Area/PubMed/Curation">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002287</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002080</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002080</idno>
<idno type="wicri:Area/Ncbi/Merge">001444</idno>
<idno type="wicri:Area/Ncbi/Curation">001444</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001444</idno>
<idno type="wicri:doubleKey">0171-2004:2006:Schubert S:oligonucleotide:based:antiviral</idno>
<idno type="wicri:Area/Main/Merge">003F71</idno>
<idno type="wicri:Area/Main/Curation">004426</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oligonucleotide-based antiviral strategies</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S." last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J." last="Kurreck">J. Kurreck</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Handbook of experimental pharmacology</title>
<title level="j" type="abbreviated">Handb. exp. pharmacol.</title>
<idno type="ISSN">0171-2004</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Handbook of experimental pharmacology</title>
<title level="j" type="abbreviated">Handb. exp. pharmacol.</title>
<idno type="ISSN">0171-2004</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antisense oligonucleotide</term>
<term>Antiviral</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Gene silencing</term>
<term>Humans</term>
<term>Oligonucleotides (pharmacology)</term>
<term>Oligonucleotides (therapeutic use)</term>
<term>Oligonucleotides, Antisense (pharmacology)</term>
<term>Oligonucleotides, Antisense (therapeutic use)</term>
<term>RNA interference</term>
<term>RNA, Catalytic (pharmacology)</term>
<term>RNA, Catalytic (therapeutic use)</term>
<term>RNA, Small Interfering (pharmacology)</term>
<term>RNA, Small Interfering (therapeutic use)</term>
<term>Review</term>
<term>Ribozyme</term>
<term>Virus Diseases (drug therapy)</term>
<term>Virus Diseases (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN catalytique (pharmacologie)</term>
<term>ARN catalytique (usage thérapeutique)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Humains</term>
<term>Maladies virales (traitement médicamenteux)</term>
<term>Maladies virales (virologie)</term>
<term>Oligonucléotides (pharmacologie)</term>
<term>Oligonucléotides (usage thérapeutique)</term>
<term>Oligonucléotides antisens (pharmacologie)</term>
<term>Oligonucléotides antisens (usage thérapeutique)</term>
<term>Petit ARN interférent (pharmacologie)</term>
<term>Petit ARN interférent (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
<term>Oligonucléotide antisens</term>
<term>Antiviral</term>
<term>RNA catalytique</term>
<term>Silence expression génique</term>
<term>Article synthèse</term>
<term>ARN interférence</term>
<term>Interférence ARN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</div>
</front>
</TEI>
<double idat="0171-2004:2006:Schubert S:oligonucleotide:based:antiviral"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Oligonucleotide-based antiviral strategies</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S." last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J." last="Kurreck">J. Kurreck</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0394917</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0394917 INIST</idno>
<idno type="RBID">Pascal:06-0394917</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000473</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000517</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000446</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000446</idno>
<idno type="wicri:doubleKey">0171-2004:2006:Schubert S:oligonucleotide:based:antiviral</idno>
<idno type="wicri:Area/Main/Merge">004647</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Oligonucleotide-based antiviral strategies</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S." last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J." last="Kurreck">J. Kurreck</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63</s1>
<s2>14195, Berlin</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Handbook of experimental pharmacology</title>
<title level="j" type="abbreviated">Handb. exp. pharmacol.</title>
<idno type="ISSN">0171-2004</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Handbook of experimental pharmacology</title>
<title level="j" type="abbreviated">Handb. exp. pharmacol.</title>
<idno type="ISSN">0171-2004</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antisense oligonucleotide</term>
<term>Antiviral</term>
<term>Gene silencing</term>
<term>RNA interference</term>
<term>Review</term>
<term>Ribozyme</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Oligonucléotide antisens</term>
<term>Antiviral</term>
<term>RNA catalytique</term>
<term>Silence expression génique</term>
<term>Article synthèse</term>
<term>ARN interférence</term>
<term>Interférence ARN</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="RBID">pubmed:16594620</idno>
<idno type="pmid">16594620</idno>
<idno type="doi">10.1007/3-540-27262-3_13</idno>
<idno type="wicri:Area/PubMed/Corpus">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002287</idno>
<idno type="wicri:Area/PubMed/Curation">002287</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002287</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002080</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002080</idno>
<idno type="wicri:Area/Ncbi/Merge">001444</idno>
<idno type="wicri:Area/Ncbi/Curation">001444</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001444</idno>
<idno type="wicri:doubleKey">0171-2004:2006:Schubert S:oligonucleotide:based:antiviral</idno>
<idno type="wicri:Area/Main/Merge">003F71</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Oligonucleotide-based antiviral strategies.</title>
<author><name sortKey="Schubert, S" sort="Schubert, S" uniqKey="Schubert S" first="S" last="Schubert">S. Schubert</name>
<affiliation wicri:level="3"><nlm:affiliation>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Institute for Chemistry (Biochemistry), Free University Berlin, Thielallee 63, 14195, Berlin</wicri:regionArea>
<placeName><region type="land" nuts="3">Berlin</region>
<settlement type="city">Berlin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kurreck, J" sort="Kurreck, J" uniqKey="Kurreck J" first="J" last="Kurreck">J. Kurreck</name>
</author>
</analytic>
<series><title level="j">Handbook of experimental pharmacology</title>
<idno type="ISSN">0171-2004</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Humans</term>
<term>Oligonucleotides (pharmacology)</term>
<term>Oligonucleotides (therapeutic use)</term>
<term>Oligonucleotides, Antisense (pharmacology)</term>
<term>Oligonucleotides, Antisense (therapeutic use)</term>
<term>RNA, Catalytic (pharmacology)</term>
<term>RNA, Catalytic (therapeutic use)</term>
<term>RNA, Small Interfering (pharmacology)</term>
<term>RNA, Small Interfering (therapeutic use)</term>
<term>Virus Diseases (drug therapy)</term>
<term>Virus Diseases (virology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN catalytique (pharmacologie)</term>
<term>ARN catalytique (usage thérapeutique)</term>
<term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Humains</term>
<term>Maladies virales (traitement médicamenteux)</term>
<term>Maladies virales (virologie)</term>
<term>Oligonucléotides (pharmacologie)</term>
<term>Oligonucléotides (usage thérapeutique)</term>
<term>Oligonucléotides antisens (pharmacologie)</term>
<term>Oligonucléotides antisens (usage thérapeutique)</term>
<term>Petit ARN interférent (pharmacologie)</term>
<term>Petit ARN interférent (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term>
<term>Oligonucleotides</term>
<term>Oligonucleotides, Antisense</term>
<term>RNA, Catalytic</term>
<term>RNA, Small Interfering</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ARN catalytique</term>
<term>Antiviraux</term>
<term>Oligonucléotides</term>
<term>Oligonucléotides antisens</term>
<term>Petit ARN interférent</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Humans</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Humains</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the age of extensive global traffic systems, the close neighborhood of man and livestock in some regions of the world, as well as inadequate prevention measures and medical care in poorer countries, greatly facilitates the emergence and dissemination of new virus strains. The appearance of avian influenza viruses that can infect humans, the spread of the severe acute respiratory syndrome (SARS) virus, and the unprecedented raging of human immunodeficiency virus (HIV) illustrate the threat of a global virus pandemic. In addition, viruses like hepatitis B and C claim more than one million lives every year for want of efficient therapy. Thus, new approaches to prevent virus propagation are urgently needed. Antisense strategies are considered a very attractive means of inhibiting viral replication, as oligonucleotides can be designed to interact with any viral RNA, provided its sequence is known. The ensuing targeted destruction of viral RNA should interfere with viral replication without entailing negative effects on ongoing cellular processes. In this review, we will give some examples of the employment of antisense oligonucleotides, ribozymes, and RNA interference strategies for antiviral purposes. Currently, in spite of encouraging results in preclinical studies, only a few antisense oligonucleotides and ribozymes have turned out to be efficient antiviral compounds in clinical trials. The advent of RNA interference now seems to be refueling hopes for decisive progress in the field of therapeutic employment of antisense strategies.</div>
</front>
</TEI>
</PubMed>
</double>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004426 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 004426 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0394917
   |texte=   Oligonucleotide-based antiviral strategies
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Oligonucleotide-based antiviral strategies

Oligonucleotide-based antiviral strategies

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri